Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Cited by (628)

Items 401–500 of 628

1. A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants
   Paroma Deb, Md. Maruf Ahmed Molla, KM Saif‐Ur‐Rahman, Manik Chandra Das, Debashish Das · 2021 · Egyptian Journal of Bronchology
2. A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
   Shu‐Hsing Cheng, Chia-En Lien, Szu‐Min Hsieh, Chien‐Yu Cheng, Wang-Da Liu, Ching-Lung Lo, Wen‐Chien Ko, Yen‐Hsu Chen, Ching‐Tai Huang, Hsiao‐Ting Chang et al. · 2022 · Vaccines
3. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults
   Prasad Suryakant Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Kewalchand Lalwani, Srikanth Prasad Tripathy, Sonali Kar, Sidram K. Raut, Praveen Kulkarni, Aditi A. Apte, Ashish Bavdekar et al. · 2023 · Scientific Reports
4. Rare COVID reactions might hold key to variant-proof vaccines
   Ewen Callaway · 2021 · Nature
5. COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration
   Francesco Nappi, Adelaide Iervolino, Sanjeet Singh Avtaar Singh · 2021 · Biomedicines
6. Covid-19: Whatever happened to the Novavax vaccine?
   Serena Tinari, Catherine Riva · 2021 · BMJ
7. Efficacy of COVID-19 Vaccination in People Living with HIV: A Public Health Fundamental Tool for the Protection of Patients and the Correct Management of Infection
   Alessio Facciolà, Smeralda D’Amato, Sebastiano Calimeri, Daniela Lo Giudice, Cristina Micali, Ylenia Russotto, Emmanuele Venanzi Rullo, Giuseppe Nunnari, Raffaele Squeri, Giovanni Francesco Pellicanò · 2022 · Infectious Disease Reports
8. Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19
   Agustín Valenzuela-Fernández, Romina Cabrera-Rodríguez, Laura Ciuffreda, Silvia Pérez-Yanes, Judith Estévez‐Herrera, Rafaela González‐Montelongo, Julia Alcoba-Flórez, Rodrigo Trujillo‐González, Diego García-Martínez de Artola, Helena Gil-Campesino et al. · 2022 · Frontiers in Bioengineering and Biotechnology
9. Acute Adverse Events at a Mass Vaccination Site after the Third and Fourth COVID-19 Vaccinations in Japan
   Tetsuya Akaishi, Tamotsu Onodera, Tatsuya Takahashi, Hideo Harigae, Tadashi Ishii · 2023 · The Tohoku Journal of Experimental Medicine
10. COVID-19 Vaccines—All You Want to Know
    Akira A. Shishido, Ashley H. Barnes, Shivakumar Narayanan, Joel V. Chua · 2023 · Seminars in Respiratory and Critical Care Medicine
11. Vaccination of pregnant women against COVID-19 under martial law: a narrative review
    Anatolija Krasnova · 2022 · Futurity Medicine.
12. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
    Seontae Kim, Mijeong Ko, Yesul Heo, Yeon-Kyeng Lee, Yunhyung Kwon, Seok-Kyoung Choi, Eunok Bahng · 2023 · Vaccine
13. Potential Application of Bionanoparticles to Treat Severe Acute Respiratory Syndrome Coronavirus-2 Infection
    Sujit Kumar Debnath, Rohit Srivastava · 2022 · Frontiers in Nanotechnology
14. Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review
    Manuela H Gschwend, Anthony M. Marchese, Dirk Poelaert, Brandy Warren, Matthew D. Rousculp, Freddy Caldera · 2025 · Vaccine
15. Heterologous prime-boost immunisation with mRNA- and AdC68-based 2019-nCoV variant vaccines induces broad-spectrum immune responses in mice
    Xingxing Li, Jingjing Liu, Wenjuan Li, Qinhua Peng, Miao Li, Zhifang Ying, Zelun Zhang, Xinyu Liu, Xiaohong Wu, Danhua Zhao et al. · 2023 · Frontiers in Immunology
16. One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial
    Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, Taisei Masuda, Mitsuhiro Mori · 2024 · Vaccine
17. Efficacy and effectiveness of COVID-19 vaccines in Africa: A systematic review
    Tajudeen Raji, Mosoka Papa Fallah, Nebiyu Dereje, Francis Kakooza, Nicaise Ndembi, Mohammed Abdulaziz, Merawi Aragaw, Jean Kaseya, Ngashi Ngongo · 2024 · PLoS ONE
18. Biometric Strategies to Improve Vaccine Immunogenicity and Effectiveness
    Vicente Javier Clemente‐Suárez, Laura Redondo-Flórez, Álvaro Bustamante-Sánchez, Alexandra Martín-Rodríguez, Rodrigo Alejandro Yañez Sepulveda, José Francisco Tornero-Aguilera · 2025 · Biomimetics
19. Innovative vaccine approaches—a Keystone Symposia report
    Jennifer Cable, Rino Rappuoli, Elizabeth J. Klemm, Gagandeep Kang, Ankur Mutreja, Gavin James Wright, Mariagrazia Pizza, Sowmya Ajay Castro, Joseph P. Hoffmann, Galit Alter et al. · 2022 · Annals of the New York Academy of Sciences
20. Current challenges in different approaches to control COVID-19: a comprehensive review
    Simran Giri, Sanjukta Sen, Rohan Singh, Paramita Paul, Ranabir Sahu, Gouranga Nandi, Tarun Kumar Dua · 2022 · Bulletin of the National Research Centre/Bulletin of the National Research Center
21. Formulation of SARS-CoV-2 Spike Protein with CpG Oligodeoxynucleotides and Squalene Nanoparticles Modulates Immunological Aspects Following Intranasal Delivery
    Hui‐Min Ho, Chiung‐Yi Huang, Chung‐Hsiang Yang, Shih‐Jen Liu, Hsin–Wei Chen, Guann‐Yi Yu, Jen‐Kun Chen, Tsung‐Hsien Chuang, Ming‐Hsi Huang · 2022 · Pharmaceutics
22. Prediction of the next major outbreak of COVID-19 in Mainland China and a vaccination strategy for it
    Yuanyuan Wu, Weike Zhou, Sanyi Tang, Robert Cheke, Wang Xia · 2023 · Royal Society Open Science
23. Guiding HIV-1 vaccine development with preclinical nonhuman primate research
    James A. Counts, Kevin O. Saunders · 2023 · Current Opinion in HIV and AIDS
24. Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets
    Ki‐Hye Kim, Noopur Bhatnagar, Jeeva Subbiah, Rong Liu, Surya Sekhar Pal, Jannatul Ruhan Raha, Phillip B Grovenstein, Chong Hyun Shin, Bao‐Zhong Wang, Sang‐Moo Kang · 2024 · Virology
25. The Genomic Landscape of Severe Acute Respiratory Syndrome Coronavirus 2
    M. Shaheen Malick, Helen Fernandes · 2021 · Advances in Molecular Pathology
26. Recent Advances on Drugs and Vaccines for COVID-19
    Fang Peng, Hao Yuan, Sixian Wu, Yifeng Zhou · 2021 · INQUIRY The Journal of Health Care Organization Provision and Financing
27. Increased Risk of Hospitalisation and Intensive Care Admission Associated With Infection With SARS-CoV-2 Variants B.1.1.7 and B.1.351 in Norway, December 2020 – May 2021
    Lamprini Veneti, Elina Marjukka Seppälä, Margrethe Larsdatter Storm, Beatriz Valcárcel Salamanca, Eirik Alnes Buanes, Nina Aasand, Umaer Naseer, Karoline Bragstad, Olav Hungnes, Håkon Bøås et al. · 2021 · SSRN Electronic Journal
28. Immunogenicity of SARS-CoV-2 infection and Ad26.CoV2.S vaccination in people living with HIV
    Khadija Khan, Gila Lustig, Mallory Bernstein, Derseree Archary, Sandile Cele, Farina Karim, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy et al. · 2021 · medRxiv
29. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
    Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, Danielle A. Wagner, Shayne F. Andrew, John-Paul M. Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T. Nurmukhambetova et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
30. Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-PLUS: Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial
    María Eugenia-Toledo-Romaní, Mayra García Carmenate, Carmen Valenzuela‐Silva, Waldemar Baldoquín Rodríguez, Marisel Martínez-Pérez, Meiby Rodríguez-González, Beatriz Paredes-Moreno, Ivis Mendoza-Hernández, Raúl González-Mugica, Oscar Samón-Tabío et al. · 2022 · SSRN Electronic Journal
31. Comparative efficacy of leading COVID-19 vaccines: A network meta-analysis
    Sanjay Rai, Shashank Shekhar Tripathi · 2025 · The Indian Journal of Medical Research
32. Establishment of a Novel Platform for Developing Oral Vaccines Based on the Surface Display System of Yeast Spores
    Chenyu Si, Jiawen Bai, Yuqing Li, Yang Li, Yi‐Shi Liu, Xiaoman Zhou, Jie Shi, Nakanishi Hideki, Zijie Li · 2025 · International Journal of Molecular Sciences
33. CircRNA-based therapeutics: Current opinions and clinical potential
    Hanyuan Liu, Xuelin Yao, Ying Long Zhou, Liang Chen · 2024 · The Innovation Medicine
34. COVID-19 Challenge: A Quest for Effective Vaccine Strategies Against Circulating and Emerging SARS-CoV-2 Variants
    Ruchika Yogesh, Noopur Srivastava, Syed Nasir Abbas Bukhari · 2022 · Current Pharmaceutical Design
35. Selective reversed-phase high-performance liquid chromatography method for the determination of intact SARS-CoV-2 spike protein
    Barry Lorbetskie, Taryn White, Marybeth Creskey, Xu Zhang, Michel Girard, Roger Y. Tam, Simon Sauvé, Huixin Lu · 2022 · Journal of Chromatography A
36. BBIBP-CorV vaccination accelerates anti-viral antibody responses in heterologous Omicron infection: A retrospective observation study in Shanghai
    Yu-Jie Bao, Liheng He, Benjie Miao, Zhengrong Zhong, Guanzhu Lu, Yupan Bai, Qiming Liang, Yunchao Ling, Ping Ji, Bing Su et al. · 2023 · Vaccine
37. SARS-CoV-2 variants of concern: the knowns and unknowns
    Richard John Lessells · 2021 · Anaesthesia Critical Care & Pain Medicine
38. The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
    Eduardo Tosta · 2021 · Exploration of Immunology
39. COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response
    Wei Yu, Emily Drzymalla, MARTA L. GWINN, Muin J. Khoury · 2022 · BMC Infectious Diseases
40. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections
    Olubukola T. Idoko, Effua Abigail Usuf, Uduak A. Okomo, Chizoba Barbara Wonodi, Kondwani Jambo, Beate Kampmann, Shabir Ahmed Madhi, Ifedayo Adetifa · 2022 · Clinical Infectious Diseases
41. Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis
    Zanair Soares Vasconcelos, Hany Abdulateif Salem, Sâmia Veiga, Fabiola Estefany Botelho de Lima, César Rogério da Silva Gonçalves, Eliane Carvalho Dos Santos, Alba Regina Jorge Brandão, Kátia do Nascimento Couceiro, Jorge Augusto de Oliveira Guerra, Maria das Graças Vale Barbosa Guerra · 2023 · Revista da Sociedade Brasileira de Medicina Tropical
42. Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2
    Marlena S. Bannick, Fei Gao, Elizabeth R. Brown, Holly Janes · 2023 · American Journal of Epidemiology
43. Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study
    Hee Kyoung Kim, Seon Kyeong Park, Seung‐Ah Choe, Eun Sun Gwak, Benjamin John Cowling, Young‐Man Kim, Sangwon Lee, Sang Won Lee, Geun-Yong Kwon, Eun Jung Jang et al. · 2024 · Vaccine
44. Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel
    Shepherd Roee Singer, Frederick J. Angulo, David L. Swerdlow, John M. McLaughlin, Itay Hazan, Netanel Ginish, Emilia Anis, Ella Mendelson, Orna Mor, Neta S. Zuckerman et al. · 2021 · SSRN Electronic Journal
45. T-cell responses induced by SARS-CoV-2 index-virus nanoparticle protein vaccine to the ancestral and omicron variants 6 months following primary vaccination
    William C. McMahon, Gaurav Kwatra, Marta Coelho Nunes, Alane Izu, Anthonet Lombard Koen, Johann Greffrath, Sharon Shalekoff, Caroline T. Tiemessen, Vivek Shinde, Chijioke Bennett et al. · 2025 · Communications Medicine
46. Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur
    Willi Fragcana Putra · 2022 · Jurnal Kedokteran Meditek
47. SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
    Rike Syahniar, Dayu Swasti Kharisma · 2022 · Clinical and Experimental Vaccine Research
48. A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants
    Yahui Zhang, Meijing Feng, Yongmei He, Fangming Liu, Rui Ma · 2022 · Frontiers in Public Health
49. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses
    Bethanie E. Wilkinson, Kinjal S. Patel, Katherine Smith, ROBERT E. WALKER, Chengbin Wang, Ann M. Greene, Gale Smith, Emily R. Smith, Marc Gurwith, Robert T. Chen · 2023 · Vaccine
50. Molecular dynamic simulation reveals spider antimicrobial peptide Latarcin-1 and human eosinophil cationic protein as peptide inhibitors of SARS-CoV-2 variants
    Cheng Cao, Aamir Mehmood, Daixi Li · 2023 · Journal of Biomolecular Structure and Dynamics
51. Clinical trials of pharmacological interventions for SARS‐CoV‐2 published in leading medical journals report adherence but not how it was assessed
    Charlotte Lee, Afolarin A. Otunla, Isabelle Brennan, Jeffrey K Aronson, David Nunan · 2023 · British Journal of Clinical Pharmacology
52. The fast-track development of COVID-19 vaccines
    Yousra A. El‐Maradny, Asmaa A. Ramadan, Vivek P. Chavda, Pankti C. Balar, Elrashdy M Moustafa Mohamed Redwan · 2024 · Elsevier eBooks
53. Analysis of the immune response in COVID-19
    Altijana Hromić‐Jahjefendić, Alaa A. A. Aljabali · 2025 · Progress in molecular biology and translational science
54. SARS-CoV-2 vaccines and their challenges against the variants
    Umid Kumar Shrestha · 2021 · Journal of Advances in Internal Medicine
55. Multidisciplinary Effort and Integrative Preparedness: A Lesson for the Foreseen Multivariate COVID-19 Pandemic Flare-Up
    Ashagrachew Tewabe Yayehrad, Ebrahim Abdela Siraj, Dawit Kumilachew Yimenu, Abyou Seyfu Ambaye, Manaye Tamrie Derseh, Andargachew Almaw, Yayeh TG · 2021 · Journal of Multidisciplinary Healthcare
56. Immunological challenges of the “new” infections: corona viruses
    Anthony R. Rees · 2022 · Elsevier eBooks
57. Randomised trials of COVID-19 vaccines in Africa – charting the path forward
    Charles Shey Wiysonge, Duduzile Edith Ndwandwe, Lindi Mathebula, Ameena Ebrahim Goga, Glenda Gray · 2022 · South African Journal of Science
58. COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity
    Suhad Daher‐Nashif, Rania Al-Anany, Menatalla Ali, Khadija Erradi, Elmoubasher Farag, Abdallah M. Abdallah, Mohamed M. Emara · 2022 · Archives of Virology
59. The health benefit of physical exercise on COVID-19 pandemic: Evidence from mainland China
    Ruofei Lin, Xiaoli Hu, Lige Guo, Junpei Huang · 2022 · PLoS ONE
60. The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa
    Daihai He, Boqiang Chen, Shi Zhao, Lewi Stone · 2023 · BMC Public Health
61. Assessing the robustness of COVID-19 vaccine efficacy trials: systematic review and meta-analysis, January 2023
    Thi Ngoc Anh Hoang, Ha‐Linh Quach, Ngoc Van Hoang, Van Thien Tran, Phạm Quang Thái, FLORIAN M. VOGT · 2023 · Eurosurveillance
62. Subunit vaccine raised against the SARS‐CoV‐2 spike of Delta and Omicron variants
    Feng Sheng, Zechang Fan, Keyue Zhou, Shanshan Ma, Mingzheng Liang, He Zhang, Yubiao Xie, Zhuo Ha, Ningyi Jin, Huijun Lu · 2023 · Journal of Medical Virology
63. Spatial vulnerability assessment of urbanites of Rawalpindi to the combined effects of climate change and pandemics using GIS mapping
    Naeem Ahmed · 2024 · Local Environment
64. COVID-19 Breakthrough Infections Among People With HIV: A Statewide Cohort Analysis
    Xueying Yang, Jiajia Zhang, Shujie Chen, Ziang Liu, Gregory A. Poland, Bankole Olatosi, Sharon Weissman, Xiaoming Li · 2024 · JAIDS Journal of Acquired Immune Deficiency Syndromes
65. Neutralization of VOCs including Delta one year post COVID-19 or vaccine
    Sebastian Havervall, Ulrika Wimmercranz Marking, Max Gordon, Henry Ng, Nina Greilert‐Norin, Sarah Lindbo, Kim G. Blom, Peter Nilsson, Mia Phillipson, Jonas Klingström et al. · 2021 · medRxiv
66. N6-Adenosine Methylation of a Single Site in SARS-CoV-2 5′-UTR Promotes Translation
    Ammar Aly, G. Scott, Mario R. Calderon, A. Haghighi · 2022 · bioRxiv
67. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
    Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Ebrahim Bhorat, Lee Fairlie, Umesh Lalloo, Mduduzi Sandile Lawrance Masilela, Dhayendre Moodley, Sherika Hanley et al. · 2024 · Human Vaccines & Immunotherapeutics
68. Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern
    Jinal N. Bhiman, Vimbai Sharon Madzorera, Qiniso Mkhize, Cathrine Scheepers, Tandile Hermanus, Frances Ayres, Zanele Makhado, Thandeka Moyo-Gwete, Carol E. Crowther, Beverley Singh et al. · 2025 · Scientific Reports
69. Scalable approach for coronavirus-like particles making based on the spike protein using Sf9 cells
    Luis Giovani Oliveira Guardalini, Thaissa Consoni Bernardino, Felipe Moura Dias, Jaci Leme, Henrique Coelho de Oliveira, Aldo Tonso, Eutímio Gustavo Fernández Núñez, Soraia Attie Calil Jorge · 2025 · Protein Expression and Purification
70. Nanotechnology-Based Vaccines
    Mohamed Hussein, Madiha Mumtaz, Iqra Nasir, Anisa Abdullahi · 2023 · Biology Medicine & Natural Product Chemistry
71. Grand Challenges in Molecular Medicine for Disease Prevention and Treatment Through Cyclical Innovation
    Masuko Katoh, Masaru Katoh · 2021 · Frontiers in Molecular Medicine
72. Clinical and immune response characteristics among vaccinated persons infected with SARS-CoV-2 delta variant: a retrospective study
    Cunjin Wang, Yong Li, Yuchen Pan, Luojing Zhou, Xi Zhang, Wei Yan, Fang Guo, Yusheng Shu, Ju Gao · 2022 · Journal of Zhejiang University SCIENCE B
73. Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
    Marek Mikołajczyk, Roman Andrzej Lewandowski, Anatoliy G. Goncharuk · 2022 · Vaccines
74. Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases
    Carmen Ka Man Cheung, Kimmy Wan Tung Law, Alvin Wing Hin Law, Man Fai Law, Rita Ho, Sunny Hei Wong · 2023 · Journal of Clinical and Translational Hepatology
75. An update on vaccine status and the role of nanomedicine against SARS‐CoV‐2: A narrative review
    Rabeya Tajnur, Refaya Rezwan, Md. Abdul Aziz, Mohammad Safiqul Islam · 2023 · Health Science Reports
76. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial
    Kenji Kuriyama, Kyoko Murakami, Kenkichi Sugiura, Sho Sakui, Ron P. Schuring, Mitsuhiro Mori · 2023 · Vaccine
77. COVID-19 mRNA vaccine degradation rate prediction using artificial intelligence techniques: A narrative review
    Hwai Ing Soon, Azian Azamimi Abdullah, Hiromitsu Nishizaki, ‪Mohd Yusoff Mashor, Latifah Munirah Kamarudin, Zeti‐Azura Mohamed‐Hussein, Zeehaida Mohamed, Wei Chern Ang · 2024 · International Journal of ADVANCED AND APPLIED SCIENCES
78. Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents
    Eun Sol Lee, Young June Choe, Seung‐Ah Choe, Eun Sun Gwak, Donghyok Kwon · 2024 · The Pediatric Infectious Disease Journal
79. Vaccination and Therapeutics
    Walid Shaban Abdella, Ahmed Nabil Selim, Sheeren Diab, Esraa Qobeia, Akram Fekry Elgazzar · 2024 · Advances in experimental medicine and biology
80. Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial
    Chijioke Bennett, Zaheer Hoosain, Anthonet Lombard Koen, Umesh Lalloo, Cheryl Emily Louw, Vongane Louisa Maluleke, Faeezah Patel, Gabriella Benadé, Esme Louise Venter, Shirley Galbiati et al. · 2024 · Journal of Infection
81. Annotating Spike Protein Polymorphic Amino Acids of Variants of SARS-CoV-2, Including Omicron
    Gusti Ngurah Mahardika, Nyoman B. Mahendra, Bayu Krisna Mahardika, Ida Bagus Kade Suardana, Made Pharmawati · 2022 · Biochemistry Research International
82. Broadly neutralizing antibodies against SARS-CoV-2 variants
    Linqi Zhang · 2022 · National Science Open
83. Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper
    Tawee Chotpitayasunondh, Dale Andrew Fisher, Po‐Ren Hsueh, Ping‐Ing Lee, Katya A. Nogales Crespo, Kiat Ruxrungtham · 2022 · International Journal of Translational Medicine
84. A brief overview of various vaccines against nCOVID19, including safety, efficacy, reported cases, clinical trials, and progress
    Sumel Ashique, Shubneesh Kumar, Himanshu Kumar, Jayita Roy, Soumen Pal, Swagata Pal · 2023 · Indian Journal of Health Sciences and Biomedical Research (KLEU)
85. Impact of glycosylation on a broad-spectrum vaccine against SARS-CoV-2
    Han-Yi Huang, Hsin-Yu Liao, Xiaorui Chen, Szu-Wen Wang, Cheng-Wei Cheng, Md. Shahed-Al-Mahmud, Ting-Hua Chen, Jennifer M. Lo, Yo-Min Liu, Yimin Wu et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
86. Transmissibility of COVID-19 among Vaccinated Individuals: A Rapid Literature Review - Update #1
    Oluwaseun Egunsola, Liza Mastikhina, Laura E. Dowsett, Brenlea Farkas, Mark Hofmeister, Lynora M. Saxinger, Fiona M Clement · 2021 · medRxiv
87. Safety and Immunogenicity of SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901 in People Living with HIV
    Shu‐Hsing Cheng, Chia-En Lien, Szu‐Min Hsieh, Chien‐Yu Cheng, Wang-Da Liu, Ching-Lung Lo, Wen‐Chien Ko, Yen‐Hsu Chen, Ching‐Tai Huang, Hsiao‐Ting Chang et al. · 2021 · medRxiv
88. Effectiveness of the Ad26.Cov2.S Vaccine in Health Care Workers in South Africa
    Linda‐Gail Bekker, Nigel Garrett, Ameena Ebrahim Goga, Lara Rosemary Fairall, Tarylee Reddy, Nonhlanhla Yende‐Zuma, Reshma Kassanjee, Shirley Collie, Ian Sanne, Andrew Boulle et al. · 2021 · SSRN Electronic Journal
89. The changing impact of vaccines in the COVID-19 pandemic
    Jamie A. Cohen, Robyn M. Stuart, Jasmina Panovska‐Griffiths, Edinah Mudimu, Romesh Abeysuriya, Cliff C. Kerr, Michael Famulare, Daniel J. Klein · 2022 · medRxiv
90. Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition
    Thandeka Nkosi, Caroline Chasara, Anele Mbatha, Mza Nsimbi, Andrea Olga Papadopoulos, Tiza L Nguni, Farina Karim, Mohomed Yunus S Moosa, Inbal Gazy, Kondwani Jambo et al. · 2022 · medRxiv
91. The innate immune response in SARS-CoV2 infection: focus on toll-like receptor 4 in severe disease outcomes
    Enrico Maggi, Nadine Landolina, F. Mariotti, E. Munari, Nicola Tumino, P. Vacca, B. Azzarone, Lorenzo Moretta · 2025 · Frontiers in Immunology
92. Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern
    Khursheed Ul Islam, Thoraya Mohamed Elhassan A-Elgadir, Sarah Afaq, Tanveer Ahmad, Jawed Iqbal · 2021 · Frontiers in Pharmacology
93. SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies
    Renuka Raman, Krishna J. Patel, Kishu Ranjan · 2022 · Springer eBooks
94. SARS-CoV-2 Variants Screening in Burkina Faso
    Serge Théophile Soubeïga, Institut de Recherche en Sciences de la Santé (IRSS) /Laboratoire de Recherche Biomédicale (LaReBio), Ouagadougou, Burkina Faso, Kinda Charlotte, Abdou Azaque Zouré, Institut de Recherche en Sciences de la Santé (IRSS) /Laboratoire de Recherche Biomédicale (LaReBio), Ouagadougou, Burkina Faso, Tégwindé Rébeca Compaore, Institut de Recherche en Sciences de la Santé (IRSS) /Laboratoire de Recherche Biomédicale (LaReBio), Ouagadougou, Burkina Faso, Sylvie Zida, Institut de Recherche en Sciences de la Santé (IRSS) /Laboratoire de Recherche Biomédicale (LaReBio), Ouagadougou, Burkina Faso, Alidou Kagembega et al. · 2022 · Journal of Medical Microbiology and Infectious Diseases
95. IgG1-Dominant Antibody Response Induced by Recombinant Trimeric SARS-CoV-2 Spike Protein with PIKA Adjuvant
    Jingxia Wang, Xinjia Mai, Yu He, Chenxi Zhu, Dapeng Zhou · 2023 · Vaccines
96. Immunogenicity of COVID-19 Vaccination in People Living with HIV: Progress and Challenges
    Jin‐Wen Song, Lili Shen, Fu‐Sheng Wang · 2023 · Infectious Diseases & Immunity
97. Coronaviruses: Pandemic SARS-CoV-2
    Benjamin John Cowling, Sook‐San Wong · 2024 · Springer eBooks
98. ISCOM-type matrix from beta-escin and glycyrrhizin saponins
    Vladimir P. Petkov, Sonya Tsibranska, Iliyan Konstantinov Manoylov, Lidiya Kechidzhieva, Kalina Ilieva, Silviya Lyubenova Bradyanova, Nikola Ralchev, Nikolina Mihaylova, Nikolai D. Denkov, Andrey Ivanov Tchorbanov et al. · 2025 · Heliyon
99. Introduction to COVID-19 Vaccines and Kidney Transplant Recipient
    Juveriya Israr, Ajay Kumar · 2025 · OBM Transplantation
100. Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?
     Giuseppe Lippi, Brandon Michael Henry, Mario Plebani · 2021 · Diagnostics